A Pilot Study Of Pirfenidone For The Treatment Of Radiation-Induced Fibrosis
OBJECTIVES:
- Determine the safety and therapeutic efficacy of pirfenidone in cancer patients with
radiation-induced fibrosis.
OUTLINE: Patients receive oral pirfenidone 3 times daily. Treatment continues for up to 2
years in the absence of disease progression or unacceptable toxicity.
Principal functional abilities are assessed at baseline, every 3 months, and at termination
of therapy.
PROJECTED ACCRUAL: A total of 10-25 patients will be accrued for this study within 1 year.
Interventional
Primary Purpose: Supportive Care
Kevin Camphausen, MD
Principal Investigator
NCI - Radiation Oncology Branch; ROB
United States: Federal Government
CDR0000068675
NCT00020631
October 2001
October 2007
Name | Location |
---|---|
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | Bethesda, Maryland 20892-1182 |